Tissue plasminogen activator (tPA), an approved coronary thrombolytic agent, can cause serious bleeding. We report the cases of six patients with intracranial hemorrhage after tPA treatment for acute myocardial infarction. None of the patients were hypertensive at admission, and only one was hypertensive during therapy. Intravenous tPA, 100 mg, was followed by continuous intravenous heparin infusion; intracranial hemorrhage occurred between 2 and 14 hours after tPA infusion ended and between 3 and 17 hours after heparin therapy was started. The partial thromboplastin time (PTT) was excessively prolonged (from 81 s to more than 150 s) in all patients at onset of intracranial hemorrhage. The intracerebral hematomas were predominantly of lobar...
OBJECTIVE: Intraventricular hemorrhage (IVH) is associated with a poor outcome. External ventricular...
SUMMARY Four patients undergoing urokinase infusion therapy for acute occlusive cerebrovascular dise...
Haemorrhagic complications of thrombolytic therapy for myocardial infarction are common. A 68 year o...
BACKGROUND: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarct...
Use of intravenous tissue-type plasminogen activator (IV tPA) for acute ischemic stroke is restricte...
AbstractIn a period of 18 months, 2,469 patients with acute myocardial infarction treated with a thr...
basilar artery thrombosis has been associated with a low rate of spontaneous symptomatic cerebral he...
Although treatment with intravenous tissue plasminogen activator (t-PA) improves clinical outcomes i...
We conducted a case series study to assess intracerebral hemorrhage (ICH) in the context of anti-pla...
Patients with intracranial haemorrhage may sometimes require antithrombotic drugs or be inadvertentl...
International audienceIntracranial hemorrhage is one of the most feared complications following brai...
INTRODUCTION: Acute ischemic stroke is an emergency which can be treated by intravenous thrombolytic...
Thrombolytic therapy is of proven and substantial benefit for patients with Acute Ischemic Stroke. B...
Alteplase (recombinant tissue plasminogen activator or rt-PA) remains the only approved treatment (a...
Intracerebral hemorrhage secondary to thrombolysis in patients with acute myocardial infarction is a...
OBJECTIVE: Intraventricular hemorrhage (IVH) is associated with a poor outcome. External ventricular...
SUMMARY Four patients undergoing urokinase infusion therapy for acute occlusive cerebrovascular dise...
Haemorrhagic complications of thrombolytic therapy for myocardial infarction are common. A 68 year o...
BACKGROUND: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarct...
Use of intravenous tissue-type plasminogen activator (IV tPA) for acute ischemic stroke is restricte...
AbstractIn a period of 18 months, 2,469 patients with acute myocardial infarction treated with a thr...
basilar artery thrombosis has been associated with a low rate of spontaneous symptomatic cerebral he...
Although treatment with intravenous tissue plasminogen activator (t-PA) improves clinical outcomes i...
We conducted a case series study to assess intracerebral hemorrhage (ICH) in the context of anti-pla...
Patients with intracranial haemorrhage may sometimes require antithrombotic drugs or be inadvertentl...
International audienceIntracranial hemorrhage is one of the most feared complications following brai...
INTRODUCTION: Acute ischemic stroke is an emergency which can be treated by intravenous thrombolytic...
Thrombolytic therapy is of proven and substantial benefit for patients with Acute Ischemic Stroke. B...
Alteplase (recombinant tissue plasminogen activator or rt-PA) remains the only approved treatment (a...
Intracerebral hemorrhage secondary to thrombolysis in patients with acute myocardial infarction is a...
OBJECTIVE: Intraventricular hemorrhage (IVH) is associated with a poor outcome. External ventricular...
SUMMARY Four patients undergoing urokinase infusion therapy for acute occlusive cerebrovascular dise...
Haemorrhagic complications of thrombolytic therapy for myocardial infarction are common. A 68 year o...